Juvmo (tavapadon)

Name: Juvmo (tavapadon) in Parkinson's disease: Perspective and time frame
Published: 2026-09-27T21:44:59-04:00

Parkinson's disease

Also known as CVL-751

Manufacturer: AbbVie
Regulatory submission: NDA submitted September 2025
Launch: Expected by Citi analysts in the third quarter of 2026
Last updated: October 1, 2026

Section

Economic information and modeling report Budget impact model

Perspective and time frame

1 evidence topic · 1 source

ICER potential budget impact analysis: time horizon and discounting

“All costs were undiscounted and estimated over a five-year time horizon.” (opens the source at this quote in a new tab)
“All costs were undiscounted and estimated over one- and five-year time horizons.” (opens the source at this quote in a new tab)